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Since its discovery, ketamine, a non-competitive N-methyl D-aspartate (NMDA) receptor
antagonist related to phencyclidine, has been linked to multiple adverse reactions
sometimes described as “out of body” and “near death experiences,” including
emergence phenomena, delusions, hallucinations, delirium, and confusion. Due to these
effects, ketamine has been withdrawn from mainstream anesthetic use in adult patients.
Evoked potentials (EPs) are utilized to monitor neural pathways during surgery, detect
intraoperative stress or damage, detect and define the level of neural lesions, and define
abnormalities. Unfortunately, many of the volatile anesthetics commonly used during
spinal and neurologic procedures suppress EP amplitude and monitoring. Ketamine has
been found in several preclinical and clinical studies to actually increase EP amplitude and
thus has been used as an analgesic adjunct in procedures where EPmonitoring is critical.
Once the gap in our knowledge of ketamine’s risks has been sufficiently addressed
in animal models, informed clinical trials should be conducted in order to properly
incorporate ketamine-based anesthetic regimens during EP-monitored neurosurgeries.
Keywords: ketamine, evoked potentials, motor evoked potentials, somatosensory evoked potentials, general
anesthesia, drug abuse, phencyclidine
INTRODUCTION
In 1977, Marcia Moore, a famous author of New Age books, shared her “cosmatrix” ketamine
experiences with Dr. Alltounian, a clinical anesthesiologist who attended one of Moore’s
workshops. After only two ketamine “trips,” they became engaged. One year later, Moore
disappeared on a cold January night after injecting herself with ketamine (Domino, 2010).
The ketamine journey began in the early 1950’s when a group of scientists from Park Davis
MI initiated studies leading to the synthesis of phencyclidine (PCP) on March 26, 1956. PCP was
responsible for a centrally mediated sensory deprivation syndrome, concluded John Stirling Meyer,
M.D., Head of Neurology at Wayne State University. Doctor Bratton, Head of Pharmaceutical
Abbreviations: PCP, Phencyclidine; IV, Intravenous; NMDA, N-methyl D-aspartate; GABA, Gamma Aminobutyric Acid; PV,
Parvalbumin; IL-6, Interleukin-6; NOX2, Nicotinamide Adenine Dinucleotide Phosphate Oxidase-2; ROS, Reactive Oxygen
Species; EP, Evoked potential; SSEP, Somatosensory Evoked Potential; MEP, Motor Evoked Potentials; DBS, Deep Brain
Stimulation; CSSEP, Cortical Somatosensory Evoked Potential; TIVA, Total Intravenous Anesthesia.
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Research at Park Davis, stated that a shorter-acting derivative of
the drug would limit emergence delirium. One of the short-acting
agents produced in his laboratory was known as “ketamine.” The
first human recipient of a subanesthetic, intravenous (IV) dose
of ketamine in August, 1964, described strange experiences “like
floating in outer space.” After a long discussion, the researchers
decided to call ketamine a “dissociative anesthetic,” because of
its ability to disconnect human subjects from their environment.
In 1973, the drug-scheduling system classified ketamine as a
schedule III. Years later, ketamine was considered schedule II
because of its increasing frequency of abuse (Domino, 2010).
Over time, ketamine was found to have multiple clinical
applications in psychiatry and anesthesiology. It has been
reported that ketamine is effective during the acute treatment
of Major Depressive Disorder episodes with suicidal ideation.
Moreover, recent studies concluded that a single sub-anesthetic
dose of ketamine was capable of decreasing depression scores in
patients with major or bipolar depression (Zarate et al., 2006;
Permoda-Osip et al., 2015). In 2011, Shlamovitz et al. reported
a case of severe respiratory failure in a patient with a history
of asthmatic exacerbations that benefited from a dissociative
dose of ketamine to avoid intubation when standard therapies
failed (Shlamovitz and Hawthorne, 2011). Ketamine has long
been used as an analgesic with multiple routes of administration,
including oral, IV, transdermal, and intranasal, to help relieve
post-operative pain (Azevedo et al., 2000). In addition, ketamine
can be used as an anesthetic during electroconvulsive therapy
when a patient cannot tolerate other anesthetics (Rasmussen
et al., 1996).
However, due to its sympathomimetic effect, ketamine use in
anesthetic procedures complicates the monitoring of anesthesia
depth, the level of hypnosis, and presents amore difficult titration
process to a proper anesthetic dose. It was also reported to
increase the difficulty of performing the wake-up test and delayed
the moment of extubation (Gruber and Morley, 1999; Frei et al.,
2007). Airway monitoring is also mandatory during ketamine-
induced anesthesia due to its effects on glandular secretions,
triggering respiratory blockage and laryngospasm even if airway
reflexes are maintained (Stevenson, 2005).
As an abused drug, ketamine is acquired under various “street
names” including “Special K.” As a recreational “club drug,”
ketamine is used worldwide because of its affordability and
dissociative and hallucinatory effects (Lim et al., 2008; Corazza
et al., 2013). In 2014, Goyal et al. published a case report of
an anesthesiologist abusing ketamine and benzodiazepines in an
attempt to cope with a stressful environment (Goyal et al., 2014).
Since its discovery, ketamine has been linked to multiple
adverse reactions including emergence phenomena, delusions,
hallucinations, delirium, and confusion, sometimes described as
“out of body” and “near death experiences” (Treston et al., 2009).
THE DISSOCIATIVE EFFECTS OF
KETAMINE: PHARMACOLOGICAL BASES
Ketamine is a non-competitive N-methyl D-aspartate (NMDA)
receptor antagonist that exerts its effect on cortical and spinal
neurons. (Martin and Lodge, 1985, 1988) Ketamine has a pKa of
7.5, a molecular weight of 238 Da, and high neuronal membrane
permeability suggesting the intracellular action of the drug (Reich
and Silvay, 1989; Lester et al., 2015). Chemically, ketamine is
closely related to PCP (Reich and Silvay, 1989). In addition
to its antagonistic effects on NMDA receptors, ketamine has
been shown to disrupt dopaminergic neurotransmission and
impair cognitive function associated with the prefrontal region
of the brain. This in turn triggers the release of glutamate with
an excitatory effect on post-synaptic, non-NMDA glutamate
receptors (Moghaddam et al., 1997).
The effects of ketamine are wide-reaching and affect
sobriety and pain perception, sight and hearing, somatosensory
perception and short-term memory, as well as vigilance and
disposition. Both the (S) and (R) enantiomers of ketamine induce
these effects at differing intensities (Oye et al., 1992).
Francois et al. suggested that acute changes to event-relatedO2
signaling in the anterior cingulate cortex may be responsible for
the slowed reaction times observed in ketamine users (Francois
et al., 2015).
Behrens et al. reported that repeated preclinical exposure
to ketamine (30mg/kg × 2) is responsible for an increase
in brain superoxide, with a disinhibition of glutaminergic
activity and increased excitatory transmission in the prefrontal
cortex. This excitotoxicity may explain the observed symptoms
and impaired function shared by chronic and subchronic
ketamine users, as well as schizophrenic patients (Behrens et al.,
2007; Sorce et al., 2010; Schiavone et al., 2013). Ketamine is
believed to enact these alternations through initial activation
of proinflammatory cytokine, interleukin-6 (IL-6), which in
turn activated the superoxide-producing enzyme, nicotinamide
adenine dinucleotide phosphate oxidase-2 (NOX2; Behrens et al.,
2008; Stone et al., 2014).
CURRENT CLINICAL APPLICATIONS
The prolonged periods of sedation observed after ketamine-
based anesthetic regimens in children and the increased rate of
emergence delirium have incited further controversy. However,
a recent study conducted by Treston et al. in pediatric patients
(n = 745) receiving IV ketamine reported that only 2.1%
of patients developed emergence delirium. Moreover, ketamine-
induced hallucinations appeared to be equally pleasant for
children as terrifying for adults (Treston et al., 2009).
Newer studies have also revealed that the short-term memory
loss produced by ketamine administration is not actually caused
by a disturbance of memory, but as a result of general sensory
perception impairment (Oye et al., 1992). Due to these effects,
ketamine was withdrawn from mainstream anesthetic use in
adult patients (Morgan and Curran, 2012). The profound
alterations made by ketamine use to a person’s cognitive state
along with emerging research reports that chronic ketamine
abuse is linked to thalamic alterations and psychotic symptoms
similar to the changes seen in schizophrenia, have provoked
research into ketamine’s effects on the brain (Stone et al., 2014).
One study found that ketamine was responsible for
neurodegenerative processes in the rat brain when infused
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continuously for 9 h in developing mice. Braun et al.
demonstrated that ketamine toxicity is dose dependent,
triggering apoptosis at low concentrations and necrosis at higher
concentrations (Morgan and Curran, 2012).
Recently, we noted a trend of increasing interest in
analyzing the effects of ketamine on evoked potential (EP)
monitoring during spinal and neurological surgeries under
general anesthesia.
Ketamine and Evoked Potentials
EPs are utilized to monitor neural pathways during surgery,
detect intraoperative stress or damage, detect neural lesions,
define the level of lesions, and define abnormalities. Visual,
brainstem auditory, somatosensory evoked potentials (SSEPs),
and motor evoked potentials (MEPs) are all widely known and
used in clinical practice (Nuwer, 1998; Braun et al., 2010).
Unfortunately, many commonly employed anesthetic agents
suppress EP amplitudes, greatly limiting the anesthesiologist
during EP-monitored surgeries.
Furmaga et al. (2014) analyzed the effects of ketamine and
propofol on MEPs in rodents with and without a conditioning
deep brain stimulus (DBS). The same lab had previously shown
that DBS increases the amplitude of MEPs. Three groups of
rodents were assigned to receive the following treatments: the
first group received a loading dose of ketamine, 75mg/kg
intramuscularly, followed by IV infusion at 125µg/kg/min,
the second and third group received propofol, 10mg/kg IV,
followed by IV infusion at either 400µg/kg/min for the standard
dose group and 800µg/kg/min for the high dose group. It
was found that the anesthetics had a statistically significant
effect on MEP. Without DBS, propofol infusion progressively
suppressed the MEP amplitude while under ketamine anesthesia
the amplitude did not change over time. The amplitude of
MEP under ketamine anesthesia was greater than the amplitude
measured under the highest dose of propofol but there was no
statistically significant difference between the propofol groups.
With different frequencies of DBS applied, under ketamine an
increase in the DBS pulse frequency resulted in a progressive
increase in MEP amplitude, reaching statistical significance at 50
and 100Hz, but no such effect was observed under the different
rates of propofol infusion. The results showed that ketamine was
capable of increasing the amplitude of MEPs with and without a
conditioning stimulus (Mason, 2004).
Independently, Iyer et al. (2010) performed an analysis of
MEP recording on rodents before and after a moderate spinal
cord injury. One group of rodents was given isoflurane anesthesia
and the other group was given ketamine, xylazine, and atropine.
Measurements of MEPs showed an almost complete suppression
of MEPs in the isoflurane group while the ketamine group
showed an ability to maintain the amplitude of these potentials
(Furmaga et al., 2014).
Publications espousing the benefits of ketamine-based
anesthetic regimens for EP-monitored procedures have not been
limited to rodents. In 2005, Erb et al. reported the case of a 4
year old child scheduled to undergo an expansion thoracoplasty
for congenital scoliosis, with no other known abnormalities
or comorbidities. Anesthesia was induced with sevoflurane,
50% nitrous oxide, and 50µg of fentanyl. Sevoflurane was
stopped after induction and propofol (50–100µg/kg/min) and
remifentanil (2µg/kg/min) started. During this surgery, no
MEPs could be recorded in the tibialis anterior muscle but
post-operative motor function was normal. Four months after
the original surgery the patient underwent another planned
procedure that required monitoring of MEPs. The same
monitoring procedures were applied; anesthesia was induced
with a 20mg bolus of ketamine, followed by an infusion of
ketamine (4mg/kg/h) and remifentanil (2µg/kg/min). During
this surgery, MEP responses were obtained in the upper
and lower extremities throughout the procedure, and spatial
facilitation was applied for the lower extremities. The report
emphasized ketamine’s ability to maintain MEP recording in a
patient where propofol previously inhibited MEP monitoring.
Study investigators concluded that EP monitoring in children
<8 y.o. of height 70–180 cm, whose small stature seems
to have an inverse correlation with the threshold stimulus
intensity necessary for MEP recording, was impossible during
propofol/N2O anesthesia. When ketamine was added to this
anesthesia regimen, MEP monitoring was possible in these
young subjects. Importantly, propofol/N2O anesthesia did not
inhibit MEP monitoring in patients over the age of eight. Thus,
patient age is an important factor to consider in planning the
anesthetic regimen for EP-monitored surgeries, and ketamine
may have particular use in the MEP monitoring of very young
patients (Iyer et al., 2010).
In 1994, Kalkman et al. randomized five healthy subjects
in three separate sessions, to receive either pentobarbital
(1.5mg/kg), droperidol (0.07mg/kg), or ketamine (1.00mg/kg),
IV. The purpose of this study was to determine if these agents
could be used to reduce the likelihood of patient awareness
during surgery while still allowingMEPmonitoring. Aminimum
interval of 1 week between drug administrations with subsequent
evaluation was allowed to ensure no overlap of drug effects.
After receiving the IV drug, subjects were stimulated using
transcranial magnetic stimulation. MEPs in the contralateral
adductor pollicis were recorded at 2, 4, 6, 10, 15, 20, and
30min following injection. Droperidol depressed the amplitude
of both MEP recordings but onset latency was unchanged.
Pentobarbital produced variable changes in the amplitude;
some MEPs were unchanged, and some were substantially
depressed, though no significant amplitude change was observed
overall. Ketamine increased the MEPs 150–220% in three of
the five subjects within 10min of injection. Though clearly
underpowered, the study concluded that droperidol can create
sustained amplitude depression, pentobarbital had a variable
effect, producing substantial MEP depression in certain subjects,
and ketamine increased amplitude in some patients while leaving
it unchanged in others. This study concluded that ketamine
was able to “facilitate elicitation” of evoked myogenic responses
in the tibialis anterior, an increase in amplitude of 150–250%
being noted. The authors encouraged further assessment of
the interactions between ketamine and opioids/nitrous oxide
in humans, as a potential anesthetic combination, able to ease
intraoperative monitoring of MEP (Erb et al., 2005).
Langeron et al. (1997) compared ketamine-midazolam and
fentanyl-midazolam anesthesia with 60% nitrous oxide in oxygen
in subjects undergoing spinal fusion surgery under general
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anesthesia. Either ketamine (3mg/kg) or fentanyl (6µg/kg) was
given IV during induction. Anesthesia was then maintained
through an infusion of 2mg/kg/h ketamine or 3µg/kg/h
fentanyl. The results were recorded while the subject was awake,
at the end of induction, at 15min, 1, and 2 h after induction,
during skin closure, and after discontinuation of nitrous oxide.
A significant decrease in cortical somatosensory evoked potential
(CSSEP) amplitude between the pre-induction value and other
time-point values was observed in the fentanyl-midazolam
group. The ketamine-midazolam group did not display any
statistically significant changes in the CSEP recordings between
time points. No significant difference in CSSEP amplitude
was noted between the fentanyl-midazolam and ketamine-
midazolam groups when compared at a single time point. The
authors concluded that, at the present, there appears to be no
advantage to using ketamine during spine surgery requiring
CSSEP monitoring. This study analyzed data obtained from 20
subjects with 10 subjects per group, reducing the statistical power
of the results. Furthermore, the use of 60% of N2O is likely to
have affected the results, due to its confounding depressant effect
on CSSEPs. The study concluded that ketamine demonstrated no
benefit during major spinal surgery when CSSEP monitoring is
required (Kalkman et al., 1994).
Schubert et al. (1990) studied ketamine’s effect on EPs
before and after administration of 70% N2O, a concentration
known to be MEP depressant. Ketamine was given IV as a
2mg/kg bolus and then maintained by continuous infusion at
a rate of 30µg/kg/h. SSEPs from median nerve stimulation
were monitored at various time points (before induction, post-
induction, after N2O was introduced, and after N2O was
discontinued). The results indicated that ketamine significantly
enhanced the cortical amplitudes of SSEPs prior to N2O
administration. However, when N2O was added, ketamine was
unable to prevent the depressant action on SSEP amplitudes,
though the authors did stated that MEP amplitudes appeared
higher than expected when only N2O was administered. Of note,
6 (38%) out of the 16 study subjects required labetalol during the
study (Langeron et al., 1997).
Furthermore, Ubags et al. (1997) performed a study on
surgical patients to determine the effect of ketamine and
etomidate on MEPs from myogenic transcranial stimulation
when supplementing sufentanil/N2O anesthesia. Anesthesia was
induced with etomidate (0.3mg/kg) and sufentanil (1.5mg/kg)
and subsequently maintained with sufentanil (0.5mg/kg/h) and
50% N2O. Before any surgical interventions that might have
damaged spinal cord functioning and at least 60min after
induction of anesthesia, either a bolus of 0.5mg/kg ketamine or
a bolus of etomidate 0.1mg/kg was administered. Transcranial
MEPs to stimulation were recorded before and after drug
administration. No significant change in either amplitude or
latency after ketamine administration was observed. Etomidate
resulted in an amplitude reduction during the first 5min after
administration; however no significant changes in amplitude
were noted after 5, 10, and 15min. This study concluded that
both ketamine and etomidate can be administered during MEP
monitoring, though transient reductions in amplitude should be
anticipated when etomidate is used (Schubert et al., 1990).
Another case involving the use of ketamine to counter
the depressive effects of N2O and sevoflurane was reported
by Penney (2010). The case report described a 15 year old
girl weighing 48 kg who underwent a 9 h scoliosis correction
surgery with SSEP and MEP monitoring. The anesthesia was
induced with 6% sevoflurane and 60% nitrous oxide. Fentanyl
(250µg), lorazepam (1mg), and rocuronium (30mg) were
also administered intravenously. Sevoflurane was eventually
discontinued when IV anesthesia was started with 0.4–
0.6mg/kg/h of ketamine, 0.9–1.2µg/kg/h dexmedetomidine,
and 1–2µg/kg/h of fentanyl. The 60% nitrous oxide in
100% oxygen was continued during the entire length of the
procedure. Fentanyl was discontinued 30min prior to the wake-
up test being performed, and dexmedetomidine and ketamine
were stopped 5–10min before test administration. Following
successful test completion, the patient then received a 50mg
bolus of propofol, a 1mg bolus of lorazepam, and new infusions
of 1.2µg/kg/h dexmedetomidine, 0.5µg/kg/h ketamine, and
1µg/kg/h fentanyl. During surgery, successful intraoperative
SSEP and MEP monitoring was performed and the patient
exhibited no neurological or motor deficits after surgery (Ubags
et al., 1997).
A similar report by Agarwal et al. (2008) described a 12 year
old female scheduled to undergo an anterior/posterior fusion of
her lumbar spine. The patient had a surgical history of a spinal
astrocytoma resection with a partial thoracic laminectomy 3 years
prior. A thoracic spinal fusion had also been performed 1 year
prior. Leg weakness was noted upon preoperative evaluation.
IV ketamine (175mg), midazolam (5mg), and d-tubocurare
(25mg) were used to induce anesthesia. During the case, IV
midazolam (0.1mg/kg/h) and ketamine (0.8mg/kg/h) were used
for anesthesia maintenance without volatile agents. For the entire
length of the procedure, SSEPs were able to be reliably monitored
on the right side but not the left. Upon closure, 50µg of fentanyl
were administered, significantly decreasing SSEP amplitude and
prolonging the EP latency (Penney, 2010).
In this patient’s previous thoracic anterior/posterior spinal
fusion, sufentanil-based anesthesia was used in addition to 70%
nitrous oxide and vecuronium. Although identical techniques
and equipment for SSEP monitoring were used, no adequate
EPs could be obtained, providing support for the superiority
of ketamine-midazolam-based anesthesia regimens during SSEP
monitoring for spinal surgery (Penney, 2010).
A recent article proposed the use of propofol-based total
intravenous anesthesia (TIVA) and opioid-based anesthesia for
optimal MEP monitoring. The article advised avoidance of
volatile anesthetics, as these agents suppress potentials (Agarwal
et al., 1998). Different studies displayed the advantages of
ketamine over isoflurane, pentobarbital, and droperidol when
motor and sensory EPs are monitored (Iyer et al., 2010).
CONCLUSION AND FUTURE DIRECTIVES
Regardless of its benefits, ketamine is no longer favored as
a mainstream anesthetic, primarily because of its ability to
trigger emergence delirium, delusions, hallucinations, and
confusion, leading to a prolonged period of post-operative
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sedation and recovery. Due to the promising effects of
ketamine-use as an adjuvant anesthetic during EP-monitored
neurosurgeries, it is worthwhile to further investigate ketamine’s
anti-inflammatory and anti-excitotoxic, dose-dependent effects
in preclinical studies. However, the clinical use of ketamine
should always be based upon the risk/benefit evaluation.
Once the gap in our knowledge of ketamine’s risks has been
sufficiently addressed in animal models, informed clinical
trials should be conducted in order to properly incorporate
ketamine-based anesthetic regimens during EP-monitored
neurosurgeries.
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